29,800 Shares in Supernus Pharmaceuticals, Inc. $SUPN Purchased by Great Lakes Advisors LLC

Great Lakes Advisors LLC bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 2nd quarter, HoldingsChannel reports. The fund bought 29,800 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,386,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in SUPN. Royal Bank of Canada lifted its holdings in shares of Supernus Pharmaceuticals by 68.1% during the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after acquiring an additional 4,729 shares during the period. AQR Capital Management LLC boosted its position in shares of Supernus Pharmaceuticals by 35.2% during the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock worth $2,791,000 after acquiring an additional 22,182 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Supernus Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock worth $978,000 after acquiring an additional 1,297 shares in the last quarter. Millennium Management LLC increased its stake in Supernus Pharmaceuticals by 370.5% in the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock valued at $4,695,000 after acquiring an additional 112,886 shares during the last quarter. Finally, Empowered Funds LLC raised its position in Supernus Pharmaceuticals by 16.0% during the first quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock valued at $1,573,000 after purchasing an additional 6,619 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have weighed in on SUPN. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Cantor Fitzgerald lifted their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $62.83.

Supernus Pharmaceuticals Trading Down 3.4%

SUPN opened at $45.85 on Friday. The company has a market cap of $2.67 billion, a P/E ratio of -23.88, a PEG ratio of 0.87 and a beta of 0.56. The company’s 50 day moving average is $46.74 and its 200-day moving average is $48.82. Supernus Pharmaceuticals, Inc. has a 1-year low of $42.45 and a 1-year high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The company had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.Supernus Pharmaceuticals’s revenue for the quarter was up 32.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.40 earnings per share. On average, equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.